Weight-Adjusted Hydroxychloroquine and Azithromycin Boosted Survival of Ventilated COVID-19 Patients by 200 Percent: Study

A new study has found that the use of weight-adjusted hydroxychloroquine (HCQ) and azithromycin (AZM) improved the survival of ventilated COVID-19 patients by nearly 200 percent.

The observational study, which hasn’t yet been peer-reviewed, was based on a re-analysis of 255 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic in the United States.

The researchers found that when the HCQ–AZM combination was given at higher dosages to treat ventilated COVID-19 patients, the risk of death was about three times lower.

“We found that when the cumulative doses...